Psychometric properties of an instrument for assessing treatment satisfaction associated with pramlintide use.

Rubin RR, Peyrot M

The Diabetes educator1 Jan 2009Cited by 15 (Europe PMC)

PMID19244569DOI10.1177/0145721708326989PepBankPUB-19244569

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

1 result from studies that gave the peptide. 1 result from people.

01HumanRandomized controlled trialOther
In patients with diabetes, composite PRAM-TSQ scores differed between pramlintide and placebo in both studies.
In plain wordsIn patients with diabetes, treatment satisfaction scores differed between pramlintide and placebo.
Peptide
Pramlintide (Symlin)
Outcome
Direction not reportedComposite treatment satisfaction score
Study
n: not reported in source
Comparator
Placebo
Outcome group
Patient-reported outcomes · Whole body
Studied dose
Dose not stated
Source sentences
Summary
Composite scores differed for pramlintide-treated and placebo-treated patients (type 1 P < .01; type 2 P < .05)
1 context sentence(design, population, supporting numbers)
Summary · context
Patients with diabetes completed the 14-item PRAM-TSQ at the end of 2 separate placebo-controlled, double-blind, randomized clinical trials in which they added active or placebo pramlintide to their established insulin regimen.
Report a problemFND-1924456903

Studies that did not test the peptide alone8

In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Pramlintide (Symlin).

02HumanNot a test of Pramlintide (Symlin) aloneObservational studyOther
In patients with diabetes, PRAM-TSQ scaling identified four treatment satisfaction components.
In plain wordsIn patients with diabetes, the questionnaire identified four treatment satisfaction components.
Peptide
Pramlintide (Symlin)
Outcome
Not applicablePRAM-TSQ components
Study
n: not reported in source
Outcome group
Patient-reported outcomes · Whole body
Source sentences
Summary
Scaling revealed 4 PRAM-TSQ components: Global Benefits, Specific Benefits, Absence of Side Effects, Treatment Preference.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients with diabetes completed the 14-item PRAM-TSQ at the end of 2 separate placebo-controlled, double-blind, randomized clinical trials in which they added active or placebo pramlintide to their established insulin regimen.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-1924456901
03HumanNot a test of Pramlintide (Symlin) aloneObservational studyOther
In patients with diabetes, composite PRAM-TSQ reliability was good in both studies.
In plain wordsIn patients with diabetes, questionnaire reliability was good in both studies.
Peptide
Pramlintide (Symlin)
Outcome
Not applicablePRAM-TSQ reliability
Study
n: not reported in source
Outcome group
Patient-reported outcomes · Whole body
Measurements
Cronbach alpha
0.93
type 1
Cronbach alpha
0.94
type 2
Source sentences
Summary
The total composite PRAM-TSQ had good reliability in both studies (type 1 alpha = .93; type 2 alpha = .94)
1 context sentence(design, population, supporting numbers)
Summary · context
Patients with diabetes completed the 14-item PRAM-TSQ at the end of 2 separate placebo-controlled, double-blind, randomized clinical trials in which they added active or placebo pramlintide to their established insulin regimen.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-1924456902
04HumanNot a test of Pramlintide (Symlin) aloneObservational studyOther
In patients with diabetes, composite PRAM-TSQ scores were associated with lower postprandial glucose.
In plain wordsIn patients with diabetes, questionnaire scores were linked to lower glucose after meals.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseComposite score association with postprandial glucose
Study
n: not reported in source
Outcome group
Patient-reported outcomes · Whole body
Source sentences
Summary
Composite scores differed for pramlintide-treated and placebo-treated patients (type 1 P < .01; type 2 P < .05), and were associated with lower PPG, weight, and insulin requirements (all P < .05).
1 context sentence(design, population, supporting numbers)
Summary · context
Patients with diabetes completed the 14-item PRAM-TSQ at the end of 2 separate placebo-controlled, double-blind, randomized clinical trials in which they added active or placebo pramlintide to their established insulin regimen.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-1924456904
05HumanNot a test of Pramlintide (Symlin) aloneObservational studyOther
In patients with diabetes, composite PRAM-TSQ scores were associated with lower weight.
In plain wordsIn patients with diabetes, questionnaire scores were linked to lower weight.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseComposite score association with weight
Study
n: not reported in source
Outcome group
Patient-reported outcomes · Whole body
Source sentences
Summary
Composite scores differed for pramlintide-treated and placebo-treated patients (type 1 P < .01; type 2 P < .05), and were associated with lower PPG, weight, and insulin requirements (all P < .05).
1 context sentence(design, population, supporting numbers)
Summary · context
Patients with diabetes completed the 14-item PRAM-TSQ at the end of 2 separate placebo-controlled, double-blind, randomized clinical trials in which they added active or placebo pramlintide to their established insulin regimen.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-1924456905
06HumanNot a test of Pramlintide (Symlin) aloneObservational studyOther
In patients with diabetes, composite PRAM-TSQ scores were associated with lower insulin requirements.
In plain wordsIn patients with diabetes, questionnaire scores were linked to lower insulin requirements.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseComposite score association with insulin requirements
Study
n: not reported in source
Outcome group
Patient-reported outcomes · Whole body
Source sentences
Summary
Composite scores differed for pramlintide-treated and placebo-treated patients (type 1 P < .01; type 2 P < .05), and were associated with lower PPG, weight, and insulin requirements (all P < .05).
1 context sentence(design, population, supporting numbers)
Summary · context
Patients with diabetes completed the 14-item PRAM-TSQ at the end of 2 separate placebo-controlled, double-blind, randomized clinical trials in which they added active or placebo pramlintide to their established insulin regimen.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-1924456906
07HumanNot a test of Pramlintide (Symlin) aloneObservational studyOther
In patients with diabetes, results for the Global Benefits and Treatment Preference PRAM-TSQ subscales were similar to the composite score results.
In plain wordsIn patients with diabetes, two questionnaire subscales gave results similar to the overall questionnaire.
Peptide
Pramlintide (Symlin)
Outcome
Not applicableGlobal Benefits and Treatment Preference subscale results
Study
n: not reported in source
Outcome group
Patient-reported outcomes · Whole body
Source sentences
Summary
Results were similar for PRAM-TSQ subscales assessing Global Benefits and Treatment Preference
1 context sentence(design, population, supporting numbers)
Summary · context
Patients with diabetes completed the 14-item PRAM-TSQ at the end of 2 separate placebo-controlled, double-blind, randomized clinical trials in which they added active or placebo pramlintide to their established insulin regimen.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-1924456907
08HumanNot a test of Pramlintide (Symlin) aloneObservational studyOther
In patients with diabetes, Specific Benefits scores were associated with lower postprandial glucose.
In plain wordsIn patients with diabetes, Specific Benefits scores were linked to lower glucose after meals.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseSpecific Benefits association with postprandial glucose
Study
n: not reported in source
Outcome group
Patient-reported outcomes · Whole body
Source sentences
Summary
Results were similar for PRAM-TSQ subscales assessing Global Benefits and Treatment Preference; Specific Benefits subscale scores were associated with lower PPG and weight (all P < .05).
1 context sentence(design, population, supporting numbers)
Summary · context
Patients with diabetes completed the 14-item PRAM-TSQ at the end of 2 separate placebo-controlled, double-blind, randomized clinical trials in which they added active or placebo pramlintide to their established insulin regimen.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-1924456909
09HumanNot a test of Pramlintide (Symlin) aloneObservational studyOther
In patients with diabetes, Specific Benefits scores were associated with lower weight.
In plain wordsIn patients with diabetes, Specific Benefits scores were linked to lower weight.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseSpecific Benefits association with weight
Study
n: not reported in source
Outcome group
Patient-reported outcomes · Whole body
Source sentences
Summary
Results were similar for PRAM-TSQ subscales assessing Global Benefits and Treatment Preference; Specific Benefits subscale scores were associated with lower PPG and weight (all P < .05).
1 context sentence(design, population, supporting numbers)
Summary · context
Patients with diabetes completed the 14-item PRAM-TSQ at the end of 2 separate placebo-controlled, double-blind, randomized clinical trials in which they added active or placebo pramlintide to their established insulin regimen.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-1924456910

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.